HC Wainwright Issues Optimistic Forecast for SANA Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Sana Biotechnology to ($0.15) per share, reflecting increased optimism from a previous estimate of ($0.18).
• Sana Biotechnology has a current market capitalization of $747.46 million, with shares trading at approximately $3.32, up by 6.6% recently.
• Six research analysts rated Sana Biotechnology with a "Buy" rating, with an average target price of $8.00, while HC Wainwright set a price objective of $11.00.

Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2025 earnings estimates for shares of Sana Biotechnology in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.18). HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.56) EPS and FY2029 earnings at ($0.41) EPS.

SANA has been the subject of a number of other reports. JMP Securities reiterated a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Sana Biotechnology has an average rating of "Buy" and an average target price of $8.00.

Sana Biotechnology Trading Up 6.6%

Shares of SANA opened at $3.32 on Thursday. The firm has a fifty day moving average price of $3.54 and a 200-day moving average price of $2.69. The firm has a market capitalization of $747.46 million, a P/E ratio of -3.13 and a beta of 1.90. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04.

Institutional Trading of Sana Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of SANA. Nisa Investment Advisors LLC boosted its holdings in Sana Biotechnology by 673.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company's stock valued at $30,000 after acquiring an additional 9,501 shares during the period. Hoey Investments Inc. purchased a new position in Sana Biotechnology during the 2nd quarter valued at about $33,000. Tower Research Capital LLC TRC boosted its holdings in Sana Biotechnology by 229.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after acquiring an additional 10,548 shares during the period. Cerity Partners LLC purchased a new position in Sana Biotechnology during the 4th quarter valued at about $25,000. Finally, Syon Capital LLC purchased a new position in Sana Biotechnology during the 4th quarter valued at about $27,000. 88.23% of the stock is owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.